By Hair loss is one of the most emotionally significant health concerns people experience – and one of the most commercially exploited. The supplement industry, the shampoo industry, and countless online “solutions” generate billions of dollars targeting people who are watching their hair thin without a clear understanding of why it’s happening or what could genuinely help.
The first and most important thing to understand: hair loss is not one condition. It’s a symptom that different conditions produce through different mechanisms. The treatment for androgenetic alopecia is completely different from the treatment for alopecia areata, which is completely different from the treatment for telogen effluvium. Getting the type right is the prerequisite for getting the treatment right.
How Hair Growth Works
Hair grows in cycles – understanding this cycle explains most hair loss patterns.
Anagen (growth phase): Active hair growth. Scalp hairs spend 2-7 years in anagen – this is what determines maximum hair length. Approximately 85-90% of scalp hairs are in anagen at any given time.
Catagen (transition phase): A brief 2-3 week transition phase where the follicle shrinks and the hair detaches from its blood supply.
Telogen (resting phase): The follicle rests for approximately 3 months. The hair is retained in the follicle but not growing – it’s shed at the end of this phase, typically when pushed out by a new anagen hair beginning to grow. Approximately 10-15% of hairs are in telogen at any given time.
Exogen: The active shedding phase – the old telogen hair is released. Normal daily shedding is approximately 50-100 hairs. This is why finding hairs in the shower isn’t pathological unless the volume increases significantly.
Type 1: Androgenetic Alopecia (Pattern Hair Loss)
The most common cause of hair loss in both men and women – affecting approximately 80 million Americans. In men it’s called male pattern baldness; in women, female pattern hair loss (FPHL). The mechanisms overlap but the clinical patterns differ.
The Mechanism
Androgenetic alopecia is driven by dihydrotestosterone (DHT) – a potent androgen derived from testosterone through the action of the enzyme 5-alpha reductase. In genetically susceptible individuals, DHT binds to androgen receptors in scalp follicles and progressively miniaturizes them – shortening the anagen phase with each cycle until the follicle produces only a thin, unpigmented vellus hair (peach fuzz) rather than a terminal hair.
The genetic susceptibility is polygenic – inherited from both sides of the family. The “you inherit baldness from your mother’s father” myth is an oversimplification; genes from both parents contribute.
Male Pattern Baldness
Follows the Norwood-Hamilton classification – typically beginning with recession at the temples, progression across the top of the scalp (vertex), and eventual confluence into broader baldness. The back and sides of the scalp (the “horseshoe” pattern) are typically spared because these follicles are androgen-insensitive.
Onset can be as early as the late teens or early 20s. Approximately 50% of men show significant hair loss by age 50.
Female Pattern Hair Loss (FPHL)
Differs from male pattern in distribution – women typically experience diffuse thinning across the crown and top of the scalp, with the frontal hairline usually preserved (Ludwig classification). Complete baldness is uncommon.
FPHL is less clearly androgen-driven than male pattern baldness – many women with FPHL have normal androgen levels. Estrogen’s protective effect on follicles likely explains why the condition accelerates significantly after menopause, when estrogen declines.
Treatments for Androgenetic Alopecia
Minoxidil (Rogaine): Available OTC as 2% and 5% topical solution/foam, and as a low-dose oral medication (2.5-5mg/day). Minoxidil prolongs the anagen phase and increases follicle size. It doesn’t block DHT – it works through a separate mechanism involving potassium channels and VEGF (vascular endothelial growth factor). Requires continuous use – stopping reverses gains within 3-6 months. Oral minoxidil has shown superior efficacy to topical in several recent trials.
Finasteride (Propecia): A 5-alpha reductase inhibitor that blocks the conversion of testosterone to DHT, reducing scalp DHT levels by approximately 70%. FDA-approved for male pattern hair loss at 1mg/day. Requires 6-12 months to assess response. Stops progression in most men and produces visible regrowth in many. Side effects: sexual dysfunction (reduced libido, erectile dysfunction, ejaculatory changes) in approximately 2-3% of users – these resolve in most men after stopping.
Dutasteride: Blocks both type I and type II 5-alpha reductase (finasteride blocks only type II), producing greater DHT suppression. More effective than finasteride in head-to-head trials. FDA-approved for BPH, used off-label for hair loss.
Spironolactone (women): An androgen-receptor blocker used for FPHL in women, particularly those with signs of hyperandrogenism. 100-200mg/day.
Low-level laser therapy (LLLT): FDA-cleared devices (laser combs, helmets, caps) stimulate follicles through photobiomodulation. Evidence of modest efficacy – meaningful for some patients, particularly in early-stage hair loss.
Hair transplant surgery: Follicular unit transplantation (FUT) or follicular unit extraction (FUE) – permanently relocate androgen-resistant follicles from the back and sides of the scalp to areas of thinning. The transplanted follicles retain their androgen resistance. Results are permanent and natural-looking with skilled surgeons. Not curative of the underlying process – medical treatment should continue alongside.
Type 2: Alopecia Areata
An autoimmune condition where the immune system attacks hair follicles – producing sudden, patchy hair loss typically in round or oval patches. Affects approximately 2% of the population at some point in their lifetime.
The Mechanism
CD8+ T cells infiltrate the hair follicle bulb and disrupt normal hair growth. The follicles are not destroyed – they’re suppressed. This is why alopecia areata can be reversible and why treatments that suppress the immune response can restore hair.
Clinical Patterns
- Alopecia areata: Patchy – one or several smooth, round patches of hair loss on the scalp or anywhere on the body
- Alopecia totalis: Complete loss of all scalp hair
- Alopecia universalis: Complete loss of all body hair including eyebrows, eyelashes, and scalp
Approximately 50% of people with limited alopecia areata recover spontaneously within a year. Prognosis worsens with extensive disease, alopecia totalis/universalis, early onset (childhood), nail involvement, and atopic disease.
Treatments for Alopecia Areata
Intralesional corticosteroid injections: First-line for limited patchy disease. Triamcinolone injected directly into patches suppresses local immune attack. Requires repeat treatment every 4-8 weeks.
Topical corticosteroids and minoxidil: For mild disease, particularly in children where injections are impractical.
JAK inhibitors – the major recent advance: Baricitinib (Olumiant) and ritlecitinib (Litfulo) are FDA-approved for severe alopecia areata. Deuruxolitinib received approval in late 2025. JAK inhibitors block the JAK-STAT signaling pathway that drives the autoimmune attack on follicles. Clinical trials showed significant hair regrowth in patients with severe disease – a genuinely transformative development for a condition that previously had no FDA-approved treatments. Require ongoing use; discontinuation leads to relapse.
Systemic corticosteroids: Can produce regrowth but relapse is common after stopping, and long-term systemic steroid use carries significant risks.
Type 3: Telogen Effluvium
A reactive, diffuse hair shedding that occurs when a significant physiological stressor triggers a large proportion of anagen hairs to prematurely shift to telogen – resulting in mass shedding approximately 2-4 months after the triggering event.
This timing is crucial and frequently confusing: the shedding occurs months after the stressor, not at the time of it. Someone who had COVID-19 in March may be alarmed by hair loss in June – these are directly connected, but the delay obscures the link.
Common Triggers
- Major surgery or general anesthesia
- Severe acute illness (including COVID-19, which has been a major driver of telogen effluvium cases)
- Significant weight loss (crash dieting, eating disorders)
- Childbirth (postpartum telogen effluvium – extremely common 2-4 months after delivery)
- Major psychological stress
- Thyroid disorders (both hypo and hyperthyroidism)
- Iron deficiency (particularly low ferritin, even without anemia)
- Vitamin D deficiency
- Sudden hormonal changes (stopping combined oral contraceptives)
- Severe nutritional deficiency
Key Characteristics
- Diffuse shedding across the entire scalp – not patchy
- Often noticed as large amounts of hair in the shower, on pillows, and in hairbrushes
- The scalp and hairline are uniformly affected (unlike androgenetic alopecia, which concentrates in specific zones)
- Hair pull test: gently pulling 50-60 hairs from the scalp yields more than 6 telogen hairs (telogen hairs have a white club-shaped root; anagen hairs have a sheath)
Prognosis and Treatment
Telogen effluvium is self-limiting – once the triggering cause resolves, the follicles re-enter anagen and hair regrows within 3-6 months. It does not cause permanent hair loss.
Treatment is largely treating the underlying cause:
- Correct iron deficiency (ferritin below 30-40 ng/mL is associated with hair loss; replete to above 70)
- Address thyroid abnormalities
- Nutritional optimization
- Manage stress where possible
- Time – the most important factor
Type 4: Traction Alopecia
Hair loss caused by chronic mechanical tension on the hair follicles – from tight hairstyles including braids, cornrows, ponytails, buns, dreadlocks, and extensions. Initially reversible; with prolonged tension, becomes permanent (follicular scarring).
Most common in women and girls with textured hair who frequently wear tight styles. Early signs: hairline recession, particularly at the temples and edges. Broken hairs and folliculitis (inflamed follicles) at the hairline.
Treatment: stopping the offending hairstyle in the early stages allows recovery. Established scarring does not recover – prevention through hair care practice modification is essential.
Type 5: Scarring Alopecias
A group of conditions involving permanent destruction of hair follicles and replacement with scar tissue – causing irreversible hair loss. Includes:
- Lichen planopilaris (LPP): An inflammatory condition; perifollicular scaling, redness, and burning
- Frontal fibrosing alopecia (FFA): A variant of LPP causing progressive recession of the frontal hairline; increasing in incidence, particularly in postmenopausal women
- Central centrifugal cicatricial alopecia (CCCA): Most common scarring alopecia in Black women; begins at the crown and spreads centrifugally
- Discoid lupus erythematosus (DLE): Scarring alopecia as a manifestation of cutaneous lupus
These conditions require prompt dermatological diagnosis and treatment to halt progression – once follicles are destroyed, the loss is permanent. Treatment targets the inflammatory process driving follicle destruction.
When to See a Doctor
- Sudden patchy hair loss (possible alopecia areata – treatable)
- Diffuse shedding following an illness or major stressor (telogen effluvium – investigate the cause)
- Hair loss with scalp symptoms: itching, scaling, redness, pain (may indicate inflammatory or scarring alopecia)
- Hair loss with other symptoms: fatigue, weight change, irregular periods (investigate thyroid, iron, hormonal causes)
- Hair loss progressing rapidly despite treatment
- Any hairline recession in women (FFA is increasingly common and underdiagnosed)
Frequently Asked Questions
How much hair loss per day is normal? 50-100 hairs per day is the generally accepted normal range. This sounds like a lot – but with approximately 100,000 hairs on the scalp, losing 100 daily represents about 0.1%. Noticeably more than your baseline is more meaningful than an absolute number.
Does wearing hats cause hair loss? No – hats don’t cause androgenetic alopecia or meaningfully accelerate it. The only caveat is extremely tight headwear worn consistently for years, which could contribute to traction alopecia at the hairband line. Casual everyday hat wearing is not a meaningful hair loss risk.
Is hair loss from minoxidil real? When starting minoxidil, some people experience increased shedding in the first 2-8 weeks – this is a real phenomenon called doffing/minoxidil shedding. It occurs because minoxidil pushes resting telogen hairs out to make way for new anagen hairs. It’s temporary and a sign the medication is working, not failing.
Can stress cause permanent hair loss? Stress-triggered telogen effluvium does not cause permanent loss – the follicles recover once the stressor resolves and the hair regrows. However, chronic severe stress can perpetuate ongoing telogen effluvium, and stress may accelerate the timeline of androgenetic alopecia in genetically predisposed individuals.
My ferritin is “normal” but my doctor says iron isn’t the problem. Could it still be contributing? Possibly. Standard laboratory “normal” ferritin ranges are wide (12-150 ng/mL in many labs). Research on hair loss suggests ferritin should ideally be above 40-70 ng/mL for optimal hair growth – a level that falls within the “normal” range but may be suboptimal for follicular function. If your ferritin is in the low-normal range (12-40 ng/mL) and you have diffuse hair shedding, it’s worth discussing iron optimization with your doctor.
Disclaimer
This article is for educational purposes only and does not constitute medical advice. Hair loss has multiple causes with different treatments – an accurate diagnosis from a qualified healthcare provider (dermatologist or trichologist) is essential before starting treatment. Do not self-treat based on this content alone.
References
- Ito T. Recent advances in the pathogenesis of autoimmune hair loss disease alopecia areata. Clinical and Developmental Immunology. 2013;2013:348546. https://doi.org/10.1155/2013/348546
- Mubki T, Rudnicka L, Olszewska M, Shapiro J. Evaluation and diagnosis of the hair loss patient: part I. Journal of the American Academy of Dermatology. 2014;71(3):415. https://doi.org/10.1016/j.jaad.2014.04.070
- Blumeyer A, Tosti A, Messenger A, et al. Evidence-based guideline for the treatment of androgenetic alopecia in women and men. Journal of the German Society of Dermatology. 2011;9(Suppl 6):S1-57. https://doi.org/10.1111/j.1610-0387.2011.07779.x
- King B, Ohyama M, Kwon O, et al. Two phase 3 trials of baricitinib for alopecia areata. New England Journal of Medicine. 2022;386(18):1687-1699. https://doi.org/10.1056/NEJMoa2110343
- Olsen EA, Messenger AG, Shapiro J, et al. Evaluation and treatment of male and female pattern hair loss. Journal of the American Academy of Dermatology. 2005;52(2):301-311. https://doi.org/10.1016/j.jaad.2004.04.008
- American Academy of Dermatology. Hair loss: diagnosis and treatment. https://www.aad.org/public/diseases/hair-loss
- National Alopecia Areata Foundation. About alopecia areata. https://www.naaf.org/alopecia-areata/
- Rushton DH. Nutritional factors and hair loss. Clinical and Experimental Dermatology. 2002;27(5):396-404. https://doi.org/10.1046/j.1365-2230.2002.01076.x
- Whiting DA. Chronic telogen effluvium: increased scalp hair shedding in middle-aged women. Journal of the American Academy of Dermatology. 1996;35(6):899-906. https://doi.org/10.1016/S0190-9622(96)90113-7
- MedlinePlus. Hair loss. https://medlineplus.gov/hairloss.html